Tag: Drug development

CMCs and Bioavailability Risks: A Comprehensive Playbook for Regulatory Optimization In the highly regulated environment of pharmaceutical drug development, bioavailability risks flagged during regulatory review can present significant challenges. These…

Managing Bioavailability Risks Identified During Tech Transfer: A Comprehensive Playbook Bioavailability risks often surface during the tech transfer phase of drug development, posing challenges for formulation and process consistency. Understanding…

Addressing Missing QbD Elements in Scale-Up Preparation: A Regulatory Compliance Playbook The pharmaceutical industry faces significant challenges during the scale-up phase of formulation development. As processes evolve from early-stage trials…

Addressing Unexplained Dissolution Variability During Early Development to Avoid Late-Stage Reformulation Dissolution variability during early development phases can pose significant challenges in formulation development. It can lead to delayed timelines,…

Strategies to Address Unexplained Dissolution Variability in Early Development Stages In the realm of pharmaceutical development, unexplained dissolution variability can pose significant challenges during formulation development. Not only does it…

Managing Bioavailability Risks During Technology Transfer: An Actionable Playbook In the highly regulated world of pharmaceutical manufacturing, one significant concern that can surface during the technology transfer phase is the…

Strategies to Address Stability Failures During Tech Transfer in Formulation Development Formulation development is a critical phase in drug manufacturing, particularly during tech transfer when production processes scale up. Failing…

Strategies for Redesigning Formulation to Address Scalability Issues in Early Development In pharmaceutical research and drug development, early-stage formulators often encounter the challenge of prototypes that are not scalable. This…

Managing Stability Failures in Formulation During Technical Transfer In the context of pharmaceutical development, achieving and maintaining stability targets during tech transfer is critical for regulatory compliance and product reliability.…

Strategies to Address Late-Stage Excipient Incompatibility During Tech Transfer In the dynamic landscape of pharmaceutical formulation, late-stage excipient incompatibility can pose significant challenges during tech transfers. Such incompatibilities often remain…

Managing Excipient Incompatibility Issues During IND/NDA Submissions Excipient incompatibility identified late during IND/NDA filing can pose significant risks to the successful registration and market launch of pharmaceutical products. These challenges…

Strategic Playbook for Managing Bioavailability Risks During Tech Transfer Managing bioavailability risk during tech transfer is a critical aspect of pharmaceutical development that requires comprehensive assessment and mitigation strategies. As…